Abionyx Pharma S.A (ABNX) | Stock Overview & Key Data
Abionyx Pharma S.A. | Small-cap | Healthcare
Abionyx Pharma S.A. | Small-cap | Healthcare
Abionyx Pharma S.A Performance Comparison
Stock Range
Today's Range
Low: €3.80
High: €4.05
on September 12, 2025
52 Week Range
Low: €1.09
High: €4.66
on April 7, 2025
on September 2, 2025
All-Time High: €14.44 on May 25, 2015
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€134.0M
EPS
-0.13
P/E Ratio (TTM)
-28.80
Forward P/E
-15.07
P/B Ratio
14.59
PEG Ratio
-15.07
Div. Yield
N/A
ROE
-56.76%
Beta
1.303
Debt to Equity
36.69
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-106.07%
Profit Margin
-96.27%
Returns and Earnings
Return on Assets (TTM)
-19.67%
Return on Equity (TTM)
-56.76%
EBITDA
€-4.3M
Net Income (TTM)
€-4.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.13
Quarterly Revenue Growth (YoY)
-12.10%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Abionyx Pharma S.A ABNX | 134.00M Small-cap | 2.39% | 132.53% | 196.92% | 211.29% | 219.01% | 208.80% | 91.09% | 394.87% |
| Abivax SA ABVX | 5.89B Large-cap | -1.51% | 18.12% | 979.82% | 1,113.20% | 884.89% | 568.84% | 705.62% | 276.97% |
| Valneva SE VLA | 677.31M Mid-cap | 2.91% | 6.87% | 42.49% | 19.69% | 68.40% | 38.43% | -52.03% | -40.88% |
| Adocia S.A ADOC | 149.89M Small-cap | 4.89% | 24.04% | 119.42% | 90.43% | 30.02% | 50.09% | 72.73% | 10.14% |
| Ose OSE | 140.66M Small-cap | 0.00% | 1.01% | 13.99% | 4.15% | -19.92% | -10.80% | -13.86% | -1.79% |
| Sensorion SA ALSEN | 92.55M Small-cap | 0.00% | 0.00% | -20.51% | -45.61% | -51.56% | -64.77% | -35.42% | -82.39% |
Ownership & Short Interest
Insider Ownership
39.01%
Institutional Ownership
4.67%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
1M
Average 90-Day Volume
570K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ABNX's 52-week high and low?
- In the last 52 weeks, Abionyx Pharma S.A reached a high of €4.66 (on September 2, 2025) and a low of €1.09 (on April 7, 2025).
- What is the market cap and P/E ratio for ABNX?
- Curious about Abionyx Pharma S.A's size and valuation? Its market capitalization stands at 134.00M. When it comes to valuation, the P/E ratio (trailing twelve months) is -28.80, and the forward P/E (looking ahead) is -15.07.
- Does ABNX pay dividends? If so, what's the yield?
- As for dividends, Abionyx Pharma S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Abionyx Pharma S.A's main competitors or similar companies to consider before investing?
When looking at Abionyx Pharma S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX5.89B Healthcare Biotechnology 568.84% 705.62% Valneva SE
VLA677.31M Healthcare Biotechnology 38.43% -52.03% Adocia S.A
ADOC149.89M Healthcare Biotechnology 50.09% 72.73% Ose
OSE140.66M Healthcare Biotechnology -10.80% -13.86% Sensorion SA
ALSEN92.55M Healthcare Biotechnology -64.77% -35.42% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Abionyx Pharma S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Abionyx Pharma S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -56.76%, the Debt to Equity ratio from the most recent quarter is 36.69, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ABNX?
- Looking at Abionyx Pharma S.A's growth, its revenue over the trailing twelve months (TTM) was €5M. Compared to the same quarter last year (YoY), quarterly revenue grew by -12.10%, and quarterly earnings saw a YoY growth of N/A.
- How much of ABNX stock is held by insiders and institutions?
- Wondering who owns Abionyx Pharma S.A stock? Company insiders (like executives and directors) hold about 39.01% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 4.67%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.